Business Wire

CA-USERTESTING

Share
UserTesting Enhances Its Machine Learning-Powered Post-Test Analysis and Redesigns Its Platform Experience for Improved Team Collaboration

UserTesting (NYSE: USER), a leader in video-based human insight , today announced advanced Instant Insight features, powered by machine learning, to help companies expedite the analysis of human insights at the test-level and accelerate time to insights. Using data-automation and proprietary models, the UserTestingⓇ Human Insight Platform can detect patterns and anomalies in the customer data, and automatically surface high-value insights within the Customer Experience Narratives. The latest product updates are designed to help companies uncover key customer perspectives more quickly, so team members can understand where to focus their efforts for greater success. In addition to English and German, UserTesting is now available in French, and customers can test in the French language with access to French speaking contributors.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220713005310/en/

New features in this product release:

Discover Patterns and Key Customer Takeaways More Quickly with Test-Level Instant Insights
UserTesting’s test-level Instant Insight feature utilizes data-driven automation and machine learning models to accelerate post-test analysis by automatically detecting patterns, anomalies, and key insights within customer data across multiple tasks and sessions. Customers can quickly identify important takeaways from their tests while alleviating the burden of lengthy post-test analysis.

Intuitively Navigate and Collaborate with UserTesting
UserTesting’s navigation redesign enables customers to access core functionalities more readily, with a new user interface, folder management, easily accessible resources, and a workspace switcher. Updates make the testing and insight management process more intuitive and accessible for broader team use, enabling scalability for growing teams across organizations. Additionally, IT departments can now manage team access more seamlessly with self-service, single sign-on, providing more governance for enterprise-scale deployments.

A Redesigned Card Sorting Experience
UserTesting has enhanced its card sorting capabilities within the UserTesting Human Insight Platform so users can view video feedback alongside card sorting metrics and gather a complete understanding of contributors’ mental models with this streamlined solution. Companies can build navigation or sitemaps based on customer expectations and behaviors, and describe categories to drive better engagement. This helps companies save costs and adapt to rapidly changing customer needs, or changes to their respective businesses, with timely feedback of how digital properties are organized and used.

En français … UserTesting
UserTesting is now available in French for both customer and contributor experiences. Companies looking to get feedback from French-speaking consumers can now do so with the UserTesting Human Insight Platform, as tests can be conducted in French, with French-speaking contributors, giving organizations the ability to target and connect with more people around the world.

Now Supports Native Video/Audio Testing
For companies wanting to test sensitive media content with greater efficiency, UserTesting enables customers to securely upload audio, video, and other media assets directly onto the Human Insight Platform with its new native media asset testing feature. Companies can gather contributor feedback easily on unreleased assets, like video and audio files, before launching them to the public.

“More than ever, it’s imperative that companies know how their customers feel, and why. UserTesting is continuously innovating its platform to help companies gain actionable insights so they can make smarter and faster business decisions,” said Kaj van de Loo, CTO at UserTesting. “UserTesting’s data-driven automation helps customers speed up analysis of video feedback, so they can make decisions quicker than ever. The platform helps companies optimize the use of human insights, so that they can better understand what is driving customer behavior, and adapt to any changes in the market.”

UserTesting will be hosting a webinar highlighting its latest product release on August 3 at 11:00 a.m. PT/2:00 p.m. ET. Register for the webinar here .

About UserTesting
UserTesting (NYSE: USER) has fundamentally changed the way organizations get insights from customers with fast, opt-in feedback and experience capture technology. The UserTesting Human Insight Platform taps into our global network of real people and generates video-based recorded experiences, so anyone in an organization can directly ask questions, hear what users say, see what they mean, and understand what it’s actually like to be a customer. Unlike approaches that track user behavior then try to infer what that behavior means, UserTesting reduces guesswork and brings customer experience data to life with human insight. UserTesting has approximately 2,500 customers, including more than half of the world’s top 100 most valuable brands according to Forbes. UserTesting is headquartered in San Francisco, California. To learn more, visit www.usertesting.com .

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Phase 1 Results for its TGFβR2×PD-1 Bispecific Antibody in Advanced Colorectal Cancer and KRAS G12D Inhibitor in Advanced Pancreatic Ductal Adenocarcinoma19.10.2025 19:30:00 CEST | Press release

Data presented at ESMO 2025 show INCA33890, a TGFβR2×PD-1 bispecific antibody, has the potential to be an effective treatment in microsatellite stable (MSS) colorectal cancerPlanned initiation of registrational program for INCA33890 in MSS colorectal cancer in 2026Maturing data for INCB161734, a KRAS G12D inhibitor, shows a favorable safety profile and evidence of clinical benefit in heavily pre-treated pancreatic ductal adenocarcinoma (PDAC) patientsIncyte will expand on the results from the oral presentations at an in-person and webcasted event on Sunday, October 19, 2025, from 1:30 – 3:00 p.m. EDT (7:30 – 9:00 p.m. CEST) Incyte (Nasdaq:INCY) announced the first clinical data evaluating its TGFβR2×PD-1 bispecific antibody (INCA33890) for patients with microsatellite stable (MSS) colorectal cancer; and its potent, selective and orally bioavailable KRAS G12D inhibitor (INCB161734) for patients with KRAS G12D mutations, specifically pancreatic ductal adenocarcinoma (PDAC). The data were

Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment19.10.2025 11:15:00 CEST | Press release

New data from pivotal Phase 3 ROSELLA trial reinforce relacorilant plus nab-paclitaxel improves progression-free and overall survival in patients with platinum-resistant ovarian cancer, with no need for biomarker selection – including in people who progressed while on or after taking a PARP inhibitor, a patient population with particularly poor prognosis Corcept expands BELLA trial to three study arms: (i) platinum-resistant ovarian cancer, (ii) platinum-sensitive ovarian cancer and (iii) endometrial cancer Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today shared new late-breaking data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer at the European Society for Medical Oncology (ESMO) 2025 Annual

Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release

– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura

ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release

ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui

Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release

With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye